There were 330 press releases posted in the last 24 hours and 150,433 in the last 365 days.

The Cholangiocarcinoma Foundation Awards $150,000 in New Research Grants for 2017

CCF’s Research Fellowship Program supports research that opens new pathways for diagnosis and drug discovery thereby accelerating a path to a cure.

CHICAGO, IL, USA, June 3, 2017 /EINPresswire.com/ -- The Cholangiocarcinoma Foundation (CCF), a nonprofit organization funding novel research for bile duct cancer has awarded the 3rd cycle of its Research Fellowship Program.

Since 2015, the Foundation has awarded $550,000 in seed funding to outstanding, young investigators to raise awareness about cholangiocarcinoma and inspire innovative, high quality research. In accordance with the CCF Research Philosophy, CCF supports promising projects that are less likely to get traditional funding. We value open-access research that catalyzes collaboration and focuses on finding a cure.

2017 award recipient Dr. Lipika Goyal shared, “As an investigator early in my career, support from the Cholangiocarcinoma Foundation is important because it provides the pilot funding for research in a rare, underfunded disease and it provides visibility for future collaboration with senior colleagues in the field.”

In 2017, 35 applications were received from world-renowned institutions in 7 countries (Canada, Italy, Mongolia, Netherlands, Thailand, United Kingdom, and the United States). Applications were accepted from not-for-profit academic, medical or research institutions world-wide. Post-doctoral Fellows and Instructors with a MD, PhD, PharmD, or DVM were eligible to apply.

“Through these studies, CCF’s Research Fellowship Program aims to gain insights and achieve significant milestones into the research of cholangiocarcinoma,” said Donna Mayer, Executive Director of the Cholangiocarcinoma Foundation. “We are proud to honor and support remarkable scientists as they carry on the legacies of those for whom the grants are named.”

2017 FELLOWSHIP RECIPIENTS:

Melissa Manza Memorial Research Fund
Targeting YAP as a Novel Therapeutic Approach for Cholangiocarcinoma
Amount: $50,000
Researcher: John Gordan, MD, PhD - University of California, San Francisco

Andrea Scott Memorial Research Fellowship
Identifying Therapeutic Strategies for FGFR inhibition in Intrahepatic Cholangiocarcinoma:
Amount: $50,000
Researcher: Lipika Goyal, MD – Massachusetts General Hospital/Harvard University

Elisabeth Dardenne Stefanini Memorial Research Fellowship
Trans-ABC06: Understanding the role of DNA-damage repair mechanisms in patients with cholangiocarcinoma: translational research in the context of the ABC06 randomized phase III clinical trial
Amount: $50,000
Researcher: Angela Lamarca, MD, PhD – The Christie NHS Foundation Trust, UK


About Cholangiocarcinoma:
Cholangiocarcinoma, a highly lethal cancer with poor prognosis, arises from the bile ducts in the liver. It is often diagnosed at advanced stages when treatment is only minimally effective, emphasizing the imminent need for novel therapies.

There are no effective strategies for prevention, early diagnosis or long-term treatment, indicating a significant unmet medical need. The risk factors and genetic causes of CC are not well known and clinical treatment options are extremely limited. Even with aggressive treatment, survival rates are low and average survival is only 6 month from diagnosis.

Although considered rare, with 5,000-6,000 cases a year being diagnosed in the US, the worldwide incidence and mortality is increasing thus research into this deadly disease is urgently needed.

About the Cholangiocarcinoma Foundation
Founded in 2006, the Cholangiocarcinoma Foundation is a global 501(c) (3) non-profit organization whose mission is to find a cure and improve the quality of life for those affected by bile duct cancer through advocacy, education, collaboration and research.

Visit The Cholangiocarcinoma Foundation website to learn more.

Jordan Giles
Cholangiocarcinoma Foundation
888-396-6731x10
email us here


EIN Presswire does not exercise editorial control over third-party content provided, uploaded, published, or distributed by users of EIN Presswire. We are a distributor, not a publisher, of 3rd party content. Such content may contain the views, opinions, statements, offers, and other material of the respective users, suppliers, participants, or authors.